Friedreich Ataxia Clinical Outcome Measures

Sean R. Regner(Children's Hospital of Philadelphia), Nicholas S. Wilcox(Children's Hospital of Philadelphia), Lisa S. Friedman(Children's Hospital of Philadelphia), Lauren Seyer(Children's Hospital of Philadelphia), Kim Schadt(Children's Hospital of Philadelphia), Karlla W. Brigatti(Children's Hospital of Philadelphia), Susan Perlman(University of California, Los Angeles), Martin B. Delatycki(Murdoch Children's Research Institute), George Wilmot(Emory University), Christopher M. Gómez(University of Chicago), Khalaf Bushara(University of Minnesota), Katherine D. Mathews(University of Iowa), S. H. Subramony(University of Florida), Tetsuo Ashizawa(University of Florida), Bernard Ravina(University of Rochester), Alicia Brocht(University of Rochester), Jennifer Farmer(Children's Hospital of Philadelphia), David R. Lynch(Children's Hospital of Philadelphia)
Journal of Child Neurology
June 29, 2012
Cited by 51

Abstract

Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia, dysarthria, and areflexia. The authors report the progress of a large international noninterventional cohort (n = 410), tracking the natural history of disease progression using the neurologic examination-based Friedreich Ataxia Rating Scale. The authors analyzed the rate of progression with cross-sectional analysis and longitudinal analysis over a 2-year period. The Friedreich Ataxia Rating Scale captured disease progression when used at 1 and 2 years following initial evaluation, with a lower ratio of standard deviation of change to mean change over 2 years of evaluation. However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached.


Related Papers

No related papers found

Powered by citation graph analysis